JP2016504362A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504362A5
JP2016504362A5 JP2015550675A JP2015550675A JP2016504362A5 JP 2016504362 A5 JP2016504362 A5 JP 2016504362A5 JP 2015550675 A JP2015550675 A JP 2015550675A JP 2015550675 A JP2015550675 A JP 2015550675A JP 2016504362 A5 JP2016504362 A5 JP 2016504362A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
albumin
composition according
item
substantially free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015550675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016504362A (ja
Filing date
Publication date
Priority claimed from US13/794,705 external-priority patent/US20140186447A1/en
Application filed filed Critical
Publication of JP2016504362A publication Critical patent/JP2016504362A/ja
Publication of JP2016504362A5 publication Critical patent/JP2016504362A5/ja
Pending legal-status Critical Current

Links

JP2015550675A 2012-12-28 2013-12-19 アルブミンおよびパクリタキセルのナノ粒子組成物 Pending JP2016504362A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261747123P 2012-12-28 2012-12-28
US61/747,123 2012-12-28
US13/794,705 US20140186447A1 (en) 2012-12-28 2013-03-11 Nanoparticle compositions of albumin and paclitaxel
US13/794,705 2013-03-11
PCT/US2013/076630 WO2014105644A1 (en) 2012-12-28 2013-12-19 Nanoparticle compositions of albumin and paclitaxel

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018030637A Division JP2018087241A (ja) 2012-12-28 2018-02-23 アルブミンおよびパクリタキセルのナノ粒子組成物

Publications (2)

Publication Number Publication Date
JP2016504362A JP2016504362A (ja) 2016-02-12
JP2016504362A5 true JP2016504362A5 (OSRAM) 2017-02-02

Family

ID=51017455

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015550675A Pending JP2016504362A (ja) 2012-12-28 2013-12-19 アルブミンおよびパクリタキセルのナノ粒子組成物
JP2018030637A Pending JP2018087241A (ja) 2012-12-28 2018-02-23 アルブミンおよびパクリタキセルのナノ粒子組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018030637A Pending JP2018087241A (ja) 2012-12-28 2018-02-23 アルブミンおよびパクリタキセルのナノ粒子組成物

Country Status (19)

Country Link
US (2) US20140186447A1 (OSRAM)
EP (1) EP2938340A4 (OSRAM)
JP (2) JP2016504362A (OSRAM)
KR (1) KR20150100903A (OSRAM)
CN (1) CN105007912A (OSRAM)
AU (1) AU2013370955B2 (OSRAM)
BR (1) BR112015015319A2 (OSRAM)
CA (1) CA2896288A1 (OSRAM)
CR (1) CR20150386A (OSRAM)
HK (1) HK1216611A1 (OSRAM)
IL (1) IL239593A0 (OSRAM)
MX (1) MX2015008361A (OSRAM)
NI (1) NI201500090A (OSRAM)
NZ (1) NZ630912A (OSRAM)
PH (1) PH12015501486B1 (OSRAM)
RU (1) RU2663687C2 (OSRAM)
SG (1) SG11201505111TA (OSRAM)
WO (1) WO2014105644A1 (OSRAM)
ZA (1) ZA201504762B (OSRAM)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
HUE042678T2 (hu) 2005-08-31 2019-07-29 Abraxis Bioscience Llc Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek
JP5933893B2 (ja) 2006-12-14 2016-06-15 アブラクシス バイオサイエンス, エルエルシー ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法
AU2008260447B2 (en) * 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
ME03596B (me) 2009-04-15 2020-07-20 Abraxis Bioscience Llc Kompozicije nanočesтica bez priona i postupci povezani sa njima
HRP20160609T1 (hr) 2010-03-26 2016-09-23 Abraxis Bioscience, Llc Postupci liječenja hepatocelularnog karcinoma
KR101894689B1 (ko) 2010-03-29 2018-09-04 아브락시스 바이오사이언스, 엘엘씨 암의 치료 방법
CA2794147A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
EP2575804A4 (en) 2010-06-04 2013-10-23 Abraxis Bioscience Llc METHOD FOR THE TREATMENT OF PANCREASCRE
KR101970342B1 (ko) 2011-04-28 2019-04-18 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물의 혈관내 전달 및 그의 용도
WO2012154861A2 (en) 2011-05-09 2012-11-15 Mayo Foundation For Medical Education And Research Cancer treatments
EP3560486A1 (en) 2011-12-14 2019-10-30 Abraxis BioScience, LLC Use of polymeric excipients for lyophilization or freezing of particles
EP2903610B1 (en) 2012-10-01 2021-11-03 Mayo Foundation For Medical Education And Research Cancer treatments
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
CA2903454A1 (en) 2013-03-12 2014-10-02 Abraxis Bioscience, Llc Methods of treating lung cancer
EP2968191B1 (en) 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
BR112015029853A2 (pt) 2013-05-30 2017-07-25 Nanobiotix uso de uma composição farmacêutica
CA2950926A1 (en) 2014-06-13 2015-12-17 Mayo Foundation For Medical Education And Research Albumin-bound paclitaxel nanoparticle/rituximab complexes for treatment of cd20-expressing lymphomas
WO2015195476A1 (en) 2014-06-16 2015-12-23 Mayo Foundation For Medical Education And Research Treating myelomas
CN104224750A (zh) * 2014-09-17 2014-12-24 四川大学 一种注射用卡巴他赛白蛋白纳米粒制剂及其制备方法
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
PT3229776T (pt) 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
JP6789960B2 (ja) 2014-11-25 2020-11-25 キュラディグム・エスアエスCuradigm Sas 医薬組成物、その調製及び使用
LT3223796T (lt) 2014-11-25 2021-10-25 Curadigm Sas Farmacinės kompozicijos, jų gamyba ir panaudojimo būdai
PL3229843T3 (pl) * 2014-11-25 2020-06-29 Curadigm Sas Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) * 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
EA201792560A1 (ru) 2015-05-28 2018-06-29 Нанобиотикс Наночастицы для применения в качестве терапевтической вакцины
EA036790B1 (ru) 2015-06-29 2020-12-22 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способ лечения злокачественной пекомы
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
US11571469B2 (en) 2016-01-07 2023-02-07 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
EP3413874A4 (en) 2016-02-12 2020-01-22 Mayo Foundation for Medical Education and Research TREATMENTS FOR BLOOD CANCER
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
AU2017238119A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
MX2019002474A (es) 2016-09-01 2019-09-18 Mayo Found Medical Education & Res Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres.
JP2019526579A (ja) 2016-09-01 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチMayo Foundation For Medical Education And Research T細胞癌を標的とする為の方法及び組成物
RU2019110071A (ru) 2016-09-06 2020-10-08 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Способы лечения злокачественных новообразований, экспрессирующих pd-l1
CN109890422A (zh) 2016-09-06 2019-06-14 梅约医学教育与研究基金会 紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法
WO2018048815A1 (en) 2016-09-06 2018-03-15 Nantibodyfc, Llc Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CN106420665B (zh) * 2016-10-28 2019-04-16 浙江省林业科学研究院 一种包裹紫杉烷类药物的白蛋白纳米颗粒载体的制备方法
WO2019070850A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. LOCAL ADMINISTRATION OF ANINEOPLASTIC PARTICLES IN COMBINATION WITH SYSTEMIC DELIVERY OF IMMUNOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
EP3768268A4 (en) 2018-03-20 2022-02-23 Abraxis BioScience, LLC METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE
US20220401374A1 (en) * 2019-09-13 2022-12-22 Purdue Research Foundation Compositions and methods for cancer treatment by enhancing antitumor immunity using tannic acid-based nanocapsules
EP4051241A4 (en) * 2019-10-28 2023-12-06 Abraxis BioScience, LLC PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN
MX2022005715A (es) * 2019-11-11 2022-09-19 Abraxis Bioscience Llc Biomarcadores para composiciones de nanoparticulas.
WO2021158937A1 (en) * 2020-02-05 2021-08-12 The Johns Hopkins University Bortezomib-loaded nanoparticles
EP4375659B1 (en) * 2022-11-28 2025-03-26 Takeda Vaccines, Inc. A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
WO2000006152A1 (en) * 1998-07-30 2000-02-10 Novopharm Biotech, Inc. Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
JP4798832B2 (ja) * 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 ヒト血清アルブミン多量体の除去方法
SG178873A1 (en) * 2009-08-25 2012-04-27 Abraxis Bioscience Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
HRP20160609T1 (hr) * 2010-03-26 2016-09-23 Abraxis Bioscience, Llc Postupci liječenja hepatocelularnog karcinoma
WO2012092712A1 (zh) * 2011-01-07 2012-07-12 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的纳米颗粒冷冻干燥粉末制剂
CN102078306A (zh) * 2011-01-11 2011-06-01 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的紫杉醇纳米颗粒冷冻干燥制剂

Similar Documents

Publication Publication Date Title
JP2016504362A5 (OSRAM)
RU2015131141A (ru) Композиции наночастиц альбумина и паклитаксела
AT515178A5 (de) Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie
JP2016513075A5 (OSRAM)
JP2012520323A5 (OSRAM)
BR112012024590A2 (pt) métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
MX2019005287A (es) Lipidos cationicos para suministro de acido nucleico y su preparacion.
NO20080202L (no) Nanopartikulaere clopidogrel og aspirin kombinasjonsformuleringer
AR095456A1 (es) Composiciones de dos componentes que contienen complejos de halogenuro de cinc y aminoácido y cisteína
Thomas et al. Intracellular delivery of doxorubicin encapsulated in novel pH-responsive chitosan/heparin nanocapsules
BR112013027674A2 (pt) "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha".
WO2015018380A3 (en) Therapeutic nanoparticles and the preparation methods thereof
JP2017517556A5 (OSRAM)
BR112019007087A2 (pt) formulações de nanopartículas e métodos de fabricação e de utilização das mesmas
MX2016000019A (es) (arnip) gen especifico relacionado con las enfermedades respiratorias, (arnip) que contiene la estructura arn oligo helicoidal, composicion que contiene la misma para prevencion o tratamiento de las enfermedades respiratorias.
BR112015019039A8 (pt) compostos antagonistas de integrina fluorados, composição farmacêutica compreendendo ditos compostos e uso destes para tratar ou prevenir uma doença ou condição mediada por uma av integrina
WO2015152693A3 (ko) 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물
JP2017525671A5 (OSRAM)
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
WO2017017063A3 (en) Nanoparticle-based liver-targeting therapy and imaging
EA201791537A1 (ru) Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение
JP2016510326A5 (OSRAM)
JP2014505702A5 (OSRAM)
MX388073B (es) Composición farmacéutica, preparación y usos de la misma.
WO2018229093A8 (en) NANOPARTICLES AS DELIVERY VEHICLES OF ACTIVE PRINCIPLES AND METHODS OF PRODUCING SAME